Literature DB >> 24706353

Effect of prophylactic medication and influence of vitreous reflux in pressure rise after intravitreal injections of anti-VEGF drugs.

Pablo Carnota-Méndez1, Carlos Méndez-Vázquez, Jaime Otero-Villar, José Antonio Saavedra-Pazos.   

Abstract

PURPOSE: To assess the efficacy of a hypotensive prophylactic medication in preventing intraocular pressure (IOP) changes after intravitreal injections, and the effect of occurrence of vitreous reflux on the variation of IOP.
METHODS: A total of 141 intravitreal injections of anti-vascular endothelial growth factor drugs (0.05 mL) were randomly distributed into 2 groups: in group 1 (n = 77), no prophylactic IOP-lowering medication was used; in group 2 (n = 64), a fixed combination of brimonidine and timolol was instilled 5 minutes before the injection. The IOP was measured before and 1, 15, and 30 minutes after the injection. The presence of vitreous reflux was recorded.
RESULTS: Despite significantly reducing the IOP by ~3 mm Hg, prophylactic medication did not prevent a transient IOP rise. A total of 22.7% of injections showed vitreous reflux, and those patients experienced much lower initial spikes. Indeed, only 6.5% out of 77 injections above 30 mm Hg within 1 minute after injection showed vitreous reflux. Only one case showed an IOP >30 mm Hg at 15 minutes, and none at 30 minutes postinjection. The IOP normalization rates over time were similar in all groups within 15 minutes.
CONCLUSIONS: Prophylactic medication instilled 5 minutes before the injection was not effective in preventing a pressure rise after intravitreal injections. Vitreous reflux decreased significantly the spike figures compared to injections with no reflux.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24706353     DOI: 10.5301/ejo.5000455

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  5 in total

1.  Paracentesis following intravitreal drug injections in maintaining physiologic ocular perfusion pressure.

Authors:  Austin Bach; Artur Filipowicz; Aaron S Gold; Azeema Latiff; Timothy G Murray
Journal:  Int J Ophthalmol       Date:  2017-12-18       Impact factor: 1.779

2.  Effect of prior glaucoma surgery on intraocular pressure immediately after anti-vascular endothelial growth factor injection.

Authors:  Jocelyn Lam; Ian Luttrell; Leona Ding; Kasra Rezaei; Jennifer R Chao; Yewlin Chee; Lisa C Olmos De Koo; Joanne C Wen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-08-06       Impact factor: 3.117

3.  Effect of prophylactic intraocular pressure-lowering medication (brinzolamide) on intraocular pressure after ranibizumab intravitreal injection: A case-control study.

Authors:  Shuang Song; Xiao-Bing Yu; Hong Dai
Journal:  Indian J Ophthalmol       Date:  2016-10       Impact factor: 1.848

4.  Sustained Intraocular Pressure Rise after the Treat and Extend Regimen at 3 Years: Aflibercept versus Ranibizumab.

Authors:  Alper Bilgic; Laurent Kodjikian; Jay Chhablani; Anand Sudhalkar; Megha Trivedi; Viraj Vasavada; Vaishali Vasavada; Shail Vasavada; Samaresh Srivastava; Deepak Bhojwani; Aditya Sudhalkar
Journal:  J Ophthalmol       Date:  2020-01-20       Impact factor: 1.909

Review 5.  Current intravitreal therapy and ocular hypertension: A review.

Authors:  Aditya Sudhalkar; Alper Bilgic; Shail Vasavada; Laurent Kodjikian; Thibaud Mathis; Fransesc March de Ribot; Thanos Papakostas; Viraj Vasavada; Vaishali Vasavada; Samaresh Srivastava; Deepak Bhojwani; Pooja Ghia; Anand Sudhalkar
Journal:  Indian J Ophthalmol       Date:  2021-02       Impact factor: 1.848

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.